( RTTNews ) - Eli Lilly and Company ( LLY ) announced the U .
FDA has approved a supplemental Biologics License Application for Taltz injection , 80 mg/mL for the treatment of pediatric patients ( ages 6 to under 18 ) with moderate to severe plaque psoriasis who are candidates for systemic therapy or phototherapy .
Taltz was approved by the FDA in March 2016 for the treatment of moderate to severe plaque psoriasis in adult patients who are candidates for systemic therapy or phototherapy .
The FDA approved Taltz for the treatment of adults with active psoriatic arthritis in December 2017 and for the treatment of adults with active ankylosing spondylitis in August 2019 .
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq , Inc .
Sign up for our newsletter to get the latest on the transformative forces shaping the global economy , delivered every Thursday .
Email Address*  Location*  Please opt-in to receive news and information about Nasdaq 's services .
If you do not opt-in you will not receive any emails from Nasdaq @ @ @ @ @ @ @ @ @ @ communications related to Products , Industry News and Events .
can always change your preferences or unsubscribe and your contact information is covered by our Privacy Policy .
